Cargando…

Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma

Anti-PD-1 immunotherapy has been extensively used in treatment of patients with advanced metastatic renal cell carcinoma (mRCC). Several prospective clinical trials showed that the combined treatment of anti-PD-1 antibody plus lenvatinib, a potent receptor tyrosine kinase inhibitor (TKI), exhibited...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Tingting, Lin, Xiaotong, Ling, Jing, Wang, Rong, Chen, Yue, Cai, Longmei, Sun, Jingyuan, Wu, Dehua, Xie, Guozhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895929/
https://www.ncbi.nlm.nih.gov/pubmed/36742302
http://dx.doi.org/10.3389/fimmu.2023.1115691
_version_ 1784881953630060544
author Tan, Tingting
Lin, Xiaotong
Ling, Jing
Wang, Rong
Chen, Yue
Cai, Longmei
Sun, Jingyuan
Wu, Dehua
Xie, Guozhu
author_facet Tan, Tingting
Lin, Xiaotong
Ling, Jing
Wang, Rong
Chen, Yue
Cai, Longmei
Sun, Jingyuan
Wu, Dehua
Xie, Guozhu
author_sort Tan, Tingting
collection PubMed
description Anti-PD-1 immunotherapy has been extensively used in treatment of patients with advanced metastatic renal cell carcinoma (mRCC). Several prospective clinical trials showed that the combined treatment of anti-PD-1 antibody plus lenvatinib, a potent receptor tyrosine kinase inhibitor (TKI), exhibited high response rate compared with single-agent sunitinib. However, whether the patients with primary resistance to PD-1 blockade could benefit from the addition of lenvatinib is still unclear. Herein, we reported a patient with mRCC who was primary resistant to pembrolizumab and achieved a durable complete response after a short-term treatment with lenvatinib. This case report indicates that the patients with primary resistance to anti-PD-1 therapy could benefit from the short-term lenvatinib in combination with anti-PD-1 therapy, and provides a useful paradigm worthy of establishing a clinical trial for mRCC patients with primary resistance to anti-PD-1 therapy.
format Online
Article
Text
id pubmed-9895929
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98959292023-02-04 Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma Tan, Tingting Lin, Xiaotong Ling, Jing Wang, Rong Chen, Yue Cai, Longmei Sun, Jingyuan Wu, Dehua Xie, Guozhu Front Immunol Immunology Anti-PD-1 immunotherapy has been extensively used in treatment of patients with advanced metastatic renal cell carcinoma (mRCC). Several prospective clinical trials showed that the combined treatment of anti-PD-1 antibody plus lenvatinib, a potent receptor tyrosine kinase inhibitor (TKI), exhibited high response rate compared with single-agent sunitinib. However, whether the patients with primary resistance to PD-1 blockade could benefit from the addition of lenvatinib is still unclear. Herein, we reported a patient with mRCC who was primary resistant to pembrolizumab and achieved a durable complete response after a short-term treatment with lenvatinib. This case report indicates that the patients with primary resistance to anti-PD-1 therapy could benefit from the short-term lenvatinib in combination with anti-PD-1 therapy, and provides a useful paradigm worthy of establishing a clinical trial for mRCC patients with primary resistance to anti-PD-1 therapy. Frontiers Media S.A. 2023-01-20 /pmc/articles/PMC9895929/ /pubmed/36742302 http://dx.doi.org/10.3389/fimmu.2023.1115691 Text en Copyright © 2023 Tan, Lin, Ling, Wang, Chen, Cai, Sun, Wu and Xie https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Tan, Tingting
Lin, Xiaotong
Ling, Jing
Wang, Rong
Chen, Yue
Cai, Longmei
Sun, Jingyuan
Wu, Dehua
Xie, Guozhu
Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma
title Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma
title_full Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma
title_fullStr Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma
title_full_unstemmed Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma
title_short Case report: Abolishing primary resistance to PD-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma
title_sort case report: abolishing primary resistance to pd-1 blockade by short-term treatment of lenvatinib in a patient with advanced metastatic renal cell carcinoma
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9895929/
https://www.ncbi.nlm.nih.gov/pubmed/36742302
http://dx.doi.org/10.3389/fimmu.2023.1115691
work_keys_str_mv AT tantingting casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma
AT linxiaotong casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma
AT lingjing casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma
AT wangrong casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma
AT chenyue casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma
AT cailongmei casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma
AT sunjingyuan casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma
AT wudehua casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma
AT xieguozhu casereportabolishingprimaryresistancetopd1blockadebyshorttermtreatmentoflenvatinibinapatientwithadvancedmetastaticrenalcellcarcinoma